TABLE 3.
Treatment details and side effects
| Parameter or side effect | No. (%) of patients or median (IQR) |
|
|---|---|---|
| Amikacin | Kanamycina | |
| Common parameters | ||
| Duration (days) of hospital stay | 92.5 (67.3–162.3) | 110.0 (90.5–186.5) |
| Duration (days) of treatment with aminoglycosides | 138.0 (69.8–187.0) | 104.0 (82.0–179.8) |
| Creatinine level (μmol/liter) after 90 days of treatment | 80.0 (66.0–93.0) | 77.0 (62.0–100.5) |
| Creatinine level (μmol/liter) after 180 days of treatment | 82.0 (70.0–95.0) | 83.5 (67.8–101.5) |
| Observed side effectsa | ||
| Nephrotoxicity | 11 (22.9) | 9 (34.6) |
| Ototoxicity | 4 (9.1) | 5 (21.7) |
a
Nephrotoxicity is defined as a serum creatinine level >1.5 times the baseline serum creatinine level at any time during treatment; ototoxicity is defined as reduced hearing at any frequency >20 dB, as determined by audiometry at any time during treatment compared to the baseline. One patient used both amikacin and kanamycin. The patient is included in the kanamycin results, since this aminoglycoside treatment represented the largest treatment period.